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e-mail address: ahmed.kamal@aintree.nhs.uk (A. Kamal).M. Loutfi a, M.R.S. Siddiqui b, A. Dhedhi a, A. Kamal c,⇑AbstractIntravitreal injections of ranibizumab (IVR) and bevacizumab (IVB) have both been used as treatments for myopic choroidal neo-
vascularisation. We aimed to produce a meta-analysis of published literature comparing IVR with IVB for the treatment of myopic
choroidal neovascularisation, by searching electronic databases from January 1950 to March 2013. Our search produced three
suitable studies that reported on 117 patients in total. The results of the meta-analysis demonstrated that the mean number of
lines improvement after IVR appeared better compared with IVB [fixed effects model: SMD = 0.46, 95% CI (0.09, 0.83),
z = 2.44, p = 0.01]. The number of patients who had a greater than 3 line improvement was similar between groups [fixed effects
model: RR = 0.95, 95% CI (0.67, 1.32), z = 0.33, p = 0.74]. At follow up there was no difference in number of those who had an
absence of leakage [fixed effects model: RR = 1.04, 95% CI (0.93, 1.16), z = 0.64, p = 0.52]. There was no statistical significance
between the two groups in relation to the number of injections [random effects model: SMD = 0.25, 95% CI (1.12, 0.61),
z = 0.57, p = 0.57]. Early evidence therefore suggests that intravitreal injections of ranibizumab are comparable to intravitreal
injections of bevacizumab in the treatment of myopic choroidal neovascularisation. Both treatments result in a statistically signif-
icant increase in visual acuity with high numbers of patients maintaining stable vision. Further studies are still needed to strengthen
results.
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Pathological Myopia (PM) is a common cause of visual
deterioration worldwide.1,2 It is estimated to be prevalent
at a rate of 2–4% in West European populations and 9–21%
in East Asian populations.1 Rates of PM are increasing world-
wide due to a variety of factors including a significant reduc-
tion in the number of hours children spend outdoors.2,3 PM
can be defined as either: a refractive error of 6 dioptres
or an axial length of 26.5 mm.4 Typically, its pathogenesis is
associated with progressive and excessive elongation of the
eyeball, leading to degenerative changes in the choroid,sclera and retina.1 Visual impairment caused by PM often
occurs in the young to middle-aged, therefore amplifying
the socioeconomic impacts of this disease.1
The natural course of PM varies amongst individuals, lead-
ing to a variation in visual deterioration.5 However, without
treatment visual prognosis is generally very poor.5–8 Degener-
ative changes that may occur with pathological myopia
include: posterior staphyloma, diffuse or patchy chorioretinal
atrophy, retinal pigment epithelial atrophy, lacquer cracks,
spontaneous subretinal haemorrhages and macular choroidal
neovascularisation (CNV).1 By far the most common
vision-threatening pathological process that occurs in PM ise:
al.com
148 M. Loutfi et al.CNV, occurring in 5–10% of these eyes.9,10 Without treatment,
CNV can have a devastating effect on vision with over 80% of
patients displaying a visual acuity of 6/60 or less five years after
the onset of CNV.5–8
Treatment options for myopic CNV include thermal
laser photocoagulation and photodynamic therapy with
verteporfin (PDT) and intravitreal injections of Anti-vascular
endothelial growth factor (Anti-VEGF) agents.1,11 In the UK,
there are currently no clinically recommended treatments
for myopic CNV.12 The most widely used treatment has been
photodynamic therapy with verteporfin as it demonstrated
enhanced visual stabilisation compared to placebo at
12 months.13 However, recent studies have demonstrated
unfavourable long-term results for PDT with verteporfin,
where at 24 months, there was no statistically significant
improvement in visual acuity or prevention of visual loss
compared to placebo.14,15
Anti-VEGF agents are commonly used in ocular disease
due to their anti-angiogenic properties. Ranibizumab and
Bevacizumab are the two most commonly used agents. In
2005, Anti-VEGF agents were first identified as having signif-
icantly positive outcomes when used in the treatment of myo-
pic CNV.16 Many clinical studies have since examined either
drug in their ability to suppress myopic CNV, consistently
reporting positive outcomes in both short and long
term.11 Moreover, Anti-VEGF injections therapy has demon-
strated superior results when compared to PDT with
verteporfin.11,17,18
Ranibizumab is a humanised monoclonal antibody frag-
ment that binds to an isoform of vascular endothelial growth
factor (VEGF), known as VEGF-A, preventing it from binding
to its receptors.19 In 2008, it was recommended by the
National Institute for Health and Clinical Excellence (NICE)
for treating Age-Related Macular Degeneration (AMD) and
has recently been recommended by NICE for treating
Diabetic Macular Oedema and myopic choroidal neovascu-
larisation.19–21 Moreover, recent clinical guidelines by the
European Commission have recommended ranibizumab for
the treatment of myopic choroidal neovascularisation.22
Bevacizumab is a humanised monoclonal full length antibody
that also binds to VEGF-A, neutralising its activity. It was
originally applied for treating metastatic cancer, however
has currently been disapproved recommendation by NICE
for this condition.23 It is currently used off-label for ocular
diseases such as AMD and PM.24 A wide economical gap
exists between both drugs with bevacizumab costing up to
100 times less.25
The purpose of this meta-analysis and systematic literature
review is to compare the efficacy and safety of ranibizumab
and bevacizumab for the treatment myopic CNV.Methods
Searching and selection
All studies examining the role of ranibizumab or bev-
acizumab for treating choroidal neovascularisation secondary
to pathological myopia between January 1950 and March
2013 were identified. We searched the MEDLINE, EMBASE
and CINAHL databases available through the NHS National
Library of Health website, the Cochrane library and PubMed
available online. A range of MESH words and text words areavailable to describe ranibizumab, bevacizumab, pathologic
myopia or choroidal neovascularisation and these terms were
used in all combinations possible to search for relevant mate-
rial. MESH words used were ‘‘Antibodies, Monoclonal,
Humanised’’, ‘‘Myopia, Degenerative’’ and ‘‘Choroidal
Neovascularisation’’. Text words used were ‘‘Ranibizumab’’,
‘‘Bevacizumab’’, ‘‘Short Sightedness’’, ‘‘Subfoveal Degenera-
tive Myopia’’, ‘‘Myopi⁄’’, ‘‘New blood vessel formation in the
choroid’’, ‘‘Lucentis’’, ‘‘Avastin’’, ‘‘Anti-VEGF’’, ‘‘Myopia,
Degenerative’’ and ‘‘Choroidal Neovascularisation’’.
Irrelevant articles, reviews and meta-analyses evident from
the titles and abstracts were excluded. Relevant articles
referenced in these publications were obtained and the
references of identified studies were searched to identify
any further studies. No language restriction was applied. A
flow chart of the literature search according to PRISMA
guidelines is shown in Fig. 1.26
Quality assessment
The methodological quality of the trials included for meta-
analysis is explained comprehensively in Tables 1 and 2.27–30
Assessment was performed by 2 authors independently
(M.R.S.S. and M.L).27–30
Data extraction
Each included article according to our review criteria
(Table 3) was reviewed by two researchers (M.R.S.S and
M.L). This was performed independently and if any conflict
arose resolution was through discussion with the authors
prior to analysis. Only papers examining the role of Intravitre-
al Injections of Anti-VEGF for treating myopic CNV in adults
and comparative studies looking at Ranibizumab versus
Bevacizumab for treating myopic CNV were included.
Our main outcome measures were mean number of lines
improvement (assessed using an Early Treatment Retinopa-
thy study chart test (EDTRS), the number of patients who
had a greater than 3 lines improvement on ETDRS and the
number of patients who had an absence of leakage at follow
up. Other outcomes included number of injections, recur-
rence of sub/intraretinal fluid, systemic adverse events and
ocular adverse events.
Data synthesis
Statistical analyses were performed using Review Manager
5.0.23 (RevMan; Cochrane Collaboration, Copenhagen).31 A
value of p < 0.05 was chosen as the significance level for out-
come measures. For continuous data, the Inverse-Variance
method was used for the combination of standardised mean
differences (SMD). Binary data were summarised as risk ratios
(RR) and combined using the Mantel–Haenszel method.32
Heterogeneity of the studies was assessed according to Q
and I2. The Q measure identifies whether the heterogeneity
was statistically significant or not and the I2 measure quanti-
fies the heterogeneity. If the heterogeneity was significant a
random effects method was used, otherwise a fixed effects
method was utilised. In a sensitivity analysis, 0.5 was added
to each cell frequency for trials in which no event occurred,
according to the method recommended by Deeks et al.33
Where standard deviations were not reported these were
Figure 1. Search strategy.
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used for the graphical display.Results
66 articles were screened for relevance. 41 articles were
found to be relevant to our study. Three articles9,34,35
were found to have useful data for the summative outcome
according to our inclusion criteria and thus were included in
the quantitative analysis in our study (Table 1). Characteristics
of each article are given in Table 4 and the results of each
study are summarised in Table 5.The three studies9,34,35 had a total of 54 patients in the
intravitreal ranibizumab group and 63 in the intravitreal
bevacizumab group (Table 4).Overall improvement in the mean best corrected visual
acuity
Three studies9,34,35 contributed to a summative outcome.
There was no significant heterogeneity amongst trials
(Q = 2.43, df = 2, p = 0.30, I2 = 18). The mean number of lines
improvement after IVR appeared better compared with IVB
[fixed effects model: RR = 0.46, 95% CI (0.09, 0.83),
z = 2.44, p = 0.001; Fig. 2].
Table 1. Modified quality score for randomised controlled trials (Jaddad
et al. and Chalmers et al.).24,25
Quality variables Gharbiya et al. Iacono et al.
Was the study described as
randomised such as using the
words randomly, random, and
randomisation? [0, 1]
1 1
Was randomisation described
and appropriate? [1, 0, 1]
1 1
Was the study described as
double blind? [0, 1]
0 1
Was method of blinding
appropriate? [1, 0, 1]
0 1
Was there a description of
withdrawals and dropouts? [0,
1]
1 1
Inclusion criteria 1 1
Exclusion criteria 1 1
Study period given 1 1
Appropriate statistical analysis 1 1
Hard end points 1 1
Sample size calculation 0 0
Baseline comparable 1 1
Any missing post op data 1 1
Allocation concealment 0 1
Analysis by intention to treat 0 1
Score 10 14
Score max 15. Poor = 1–5 Fair = 6–10 Good = 11–15
Table 2. Methodological qualities of retrospective studies included in the
trial. Adapted from the Scottish Intercollegiate Guidelines Network and
Rangel et al.26,27
Quality variables Lai
et al.
Inclusion criteria 1
Exclusion criteria 1
Demographics comparable? 1
Can the number of participating centres be determined 1
Can the number of clinicians who participated be
determined
0
Can the reader determine where the authors are on the
learning curve for the reported investigative procedure
1
Is the technique adequately described 1
Is there any way that they have tried to standardise the
technique
1
Is the age and range given for patients 1
Do authors address whether there is any missing data 0
Were patients in each group treated along similar
timelines
1
Dropout rates stated 1
Outcomes clearly defined? 1
Blind comparators 0
Analysis by intention to treat 0
Score 11
Total 15 Less than 6 – Poor quality. 6–10 – Fair quality. 11 or more –
Good quality
Table 3. Inclusion criteria.
 All studies comparing ranibizumab and bevacizumab for the treatment of
myopic choroidal neovascularisation
 Trials on patients of any age or sex
 Trials in all languages
 Participants of any ethnicity
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improvement of 3 lines or more
Three studies9,34,35 contributed to a summative outcome.
There was no significant heterogeneity amongst trials
(Q = 2.01, df = 2, p = 0.37, I2 = 0). The number of patients
who had a greater than 3 line improvement was similar
between groups [fixed effects model: RR = 0.95, 95% CI
(0.67, 1.32), z = 0.33, p = 0.74; Fig. 3].
No. of patients with an absence of leakage at follow up
Three studies9,34,35 reported on absence of leakage at fol-
low up. There was no significant heterogeneity amongst trials
(Q = 3.77, df = 2, p = 0.15, I2 = 47). At follow up there was no
difference in number of those who had an absence of leakage
[fixed effects model: RR = 1.04, 95% CI (0.93, 1.16), z = 0.64,
p = 0.52; Fig. 4].
Overall number of injections required
There was significant heterogeneity amongst trials
(Q = 10.55, df = 2, p = 0.005, I2 = 81); therefore the fixed
effects model was inappropriate.9,34,35 There was no statisti-
cal significance between the two groups in relation to the
number of injections [random effects model: SMD = 0.25,
95% CI (1.12, 0.61), z = 0.57, p = 0.57; Fig. 5].
Recurrence of leakage
There was not enough data to produce a meaningful sum-
mative outcome. Individual studies9,34 showed no recurrence
of CNV during the follow-up periods. No significant differ-
ence in recurrence was found between the ranibizumab and
bevacizumab groups in any of the studies examined.9,34,35
Complications
There was not enough data to produce a meaningful sum-
mative outcome. No ocular or systemic adverse events were
recorded in the studies performed by Iacono et al. and Gha-
rbiya et al.9,34 Some ocular adverse events were encountered
in the Lai et al. study, with five occurring in the bevacizumab
group and four in the ranibizumab group.35 The most com-
mon ocular complication was a cataract (two in the bev-
acizumab and one in the ranibizumab group); these were
treated with surgery.35 Only two patients lost three or more
lines on the ETDRS chart as a result of an ocular complication,
both patients came from the bevacizumab group.35Discussion
Photodynamic therapy with verteporfin has been the most
widely used treatment for myopic CNV as it demonstrated
stabilisation of vision with short term treatment in compari-
son to placebo.13,34 However, recently it has fallen out of
favour as it was shown to have poor long-term visual out-
comes with a high percentage of patient developing reoccur-
rence of intraretinal fluid.14,15 Moreover, as many patients
with PM had pre-existing retinal pigment epithelial atrophy,
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nal atrophy.15,36
Recently, VEGF has been demonstrated to play a major
role in the pathogenesis of myopic CNV.16,37 Intravitreal
Anti-VEGF injections have demonstrated significant visual
and anatomical outcomes in both short-term (6 months)
and long-term studies (up to 36 months).17,38 Moreover,
Baba et al. and Yoon et al. demonstrated superior visual out-
comes following Anti-VEGF therapy compared with PDT at
12 and 24 months respectively.18,39
There are currently two Anti-VEGF drugs which are widely
used, ranibizumab and bevacizumab. Variation between both
drugs exists from a basic science perspective, suggesting a
superior clinical action with ranibizumab.34 The main differ-
ence between the two drugs is molecular weight, rani-
bizumab has a lower molecular weight (48 kDa) compared
to bevacizumab (149 kDa), suggesting that ranibizumab
should have higher and faster retinal penetration.34
Moreover, ranibizumab is more affinity-matured than bev-
acizumab, suggesting that it will have more robust molecular
binding with VEGF molecules.11 So far, comparison of clinical
data through both indirect and direct methods has failed to
affirm superiority for either drug.40,41Main findings
In this meta-analysis, we quantitatively analysed three
studies that directly compared ranibizumab with bev-
acizumab for treatment of myopic CNV. Our results
demonstrate that the mean improvement in visual acuity of
both groups was similar, with the summative outcome slightly
favouring ranibizumab.9,34,35 Another visual outcome
assessed was the number of patients with greater than 3 lines
improvement, which demonstrated a similar outlook in both
groups, across all studies.9,34,35 Moreover, anatomical
outcomes such as absence of leakage and reoccurrence of
leakage (assessed with Fluorescein Fundus Angiography
(FFA) and Ocular coherence tomography (OCT)) showed very
similar outcomes in both groups.9,34,35 Furthermore, the
number of injections required was similar between the two
groups in all three studies.9,34,35 The occurrence of ocular
and systemic adverse events was infrequent, generally mild
to moderate in intensity and treatable in most cases.9,34,35Importance
Anti-VEGF therapy has now been clinically recommended
by several studies as a first line therapy for myopic CNV.11,40
Its clinical use will vary depending on a number of factors
such as availability and cost.25
Demonstrating similar efficacies between the two Anti-
VEGF agents will further establish both agents for treating
this challenging condition. This will prove useful for clinicians
as it provides additional scope for drug switching and
alternatives in cases where patients experience poor visual
outcomes or side effects to one but not the other
drug.9,34,35
A number of large multi-centre randomised clinical trials
examining ranibizumab and bevacizumab for treating AMD
recently demonstrated comparable efficacy and safety
between the two Anti-VEGF agents.24,42–44 Results from our
study cannot be applied to AMD due to variations in thepathogenesis. However, we may infer that VEGF agents play
a similar role in generating CNV when secondary to either
AMD or PM.37Appraisal of evidence
The first study to examine Anti-VEGF treatment for myo-
pic CNV reported that bevacizumab therapy resulted in an
improvement in visual acuity and reduction in sub/intra reti-
nal fluid was provided by Nguyen et al. in 2005.16 There
has since been a plethora of studies examining either rani-
bizumab or bevacizumab therapy for the treatment of myopic
CNV, mainly from small case-series, with no randomisation or
control groups.4 Both treatments have consistently resulted
in statistically significant visual and anatomical gains at both
short-term and long-term measures.11 However, variation in
visual outcomes between studies is profound; ranibizumab
studies have demonstrated an improvement in visual acuity
ranging from 8 letters to 19.3 letters improvement, while
bevacizumab studies have demonstrated a range of 3.4 letter
improvements to 18.2 letter improvements.41 This variation
could be due to disparities in protocols, as some studies used
an initial treatment of three injections (monthly) while others
used only one injection (further treatment in the vast majority
of studies was according to visual and anatomical findings
(e.g. OCT)).11 Moreover, it could be as a result of disparity
in dosage, as bevacizumab therapy was used in doses of
1 mg, 1.25 mg, 1.5 mg or 2.5 mg.11 Furthermore, it could
be as a result of variation in the participants’ baseline charac-
teristics, presenting visual acuity, including differences in
CNV dimensions, duration of symptoms or choroidal thick-
ness.45 In addition, there could also be intrinsic differences
between drugs.
With regards to anatomical outcomes, the majority of
studies examining Anti-VEGF for myopic CNV reported a
reduction in sub/intraretinal fluid measured with FFA or
OCT in P80% of patients on final follow-up.41 Furthermore,
all studies have demonstrated acceptable safety profiles for
intravitreal Anti-VEGF injections.11 However, Anti-VEGF
agents are known to cause serious adverse events such as
intraocular inflammation and chorioretinal atrophy.46–48Heterogeneity
Amongst the studies used in the quantitative analysis, two
studies were done prospectively9,34 and one retrospec-
tively.35 There was heterogeneity between the studies with
regards to length of study period (Gharbiya et al.: 6 months,
Iacono et al.: 18 months and Lai et al.: 24 months)9,34,35
(Table 4). Only ‘‘end-of-study’’ results were analysed in this
meta-analysis which is a limitation.
Patient demographics were comparable in terms of age
and male:female ratio.9,34,35 Two studies had no statistically
significant differences in baseline characteristics between
the IVR and IVB groups (including mean visual acuity, lens sta-
tus and refractive error)9,38, while one study demonstrated
statistically significant longer duration of symptoms and
worse baseline visual acuity in the IVR group compared to
the IVB group at baseline.35 The inclusion and exclusion crite-
ria were comparable in all of the studies; all participants had
treatment-naïve myopic CNV with no other ocular disease
that could affect visual acuity.9,34,35
Table 4. Characteristics of trials comparing ranibizumab vs bevacizumab for the treatment of myopic choroidal neovascularisation.
Trial Year Type N Type f/up Intravitreal injection protocol Population
characteristics
Gharbiya
et al.
2010 Rani 16 RCT 6 0.5 mg/0.05 mL of ranibizumab;1.25 mg/0.05 mL of bevacizumab;
Re-treatment based on presence of intra/subretinal fluid
Mean age (sd): 60.63
(10.48); m:f: 4:12
Bev 16 Mean age (sd) 59.06
(11.42). m:f: 6:10
Iacono
et al.
2012 Rani 23 RCT 18 0.5 mg/0.05 mL of ranibizumab;1.25 mg/0.05 mL of bevacizumab;
re-treatment based on presence of either intra/subretinal fluid,
leakage or a new haemorrhage
Mean age 65 (sd 12),
m:f:7:20
Bev 25 Mean age 61 (sd 11),
m:f: 6:22
Lai et al. 2012 Rani 15 Retro 24 0.5 mg/005 mL of ranibizumab; 1.25 mg/0.05 mL of bevacizumab;
After 3 injections (1/month), re-treatment based on new symptoms/
persistent/recurrent angiogenic leakage
Mean age 58.9 (sd 10.5),
m:f:3/12
Bev 22 Mean age 56.3 (sd 14.6),
m:f:11:11
Rani = ranibizumab; Bev = bevacizumab; f/up = follow up; Retro = retrospective; RCT = randomised controlled trial.
Table 5. Outcomes of the studies comparing ranibizumab vs bevacizumab for the treatment of myopic choroidal neovascularisation.
Study Year Type N Overall mean
BCVA [LMC]
improvement
(Lines)
BCVA
improved
P3 lines
(Overall)
Recurrence
(Overall)
Absence of
leakage
No. injections
(Overall)
Systemic
complications
Ocular
adverse
event
Gharbiya
et al.
2010 Rani 16 3.46 SD = 2.22 9 0 15 2.81 (range 1–5) 0 0
Bev 16 3.17 SD = 1.68 10 0 16 2.44 (range 1–5) 0 0
Iacono
et al.
2012 Rani 23 1.8 SD = 0.27 7 n/a 23 2.56 (range 1–6) 0 0
Bev 25 1.7 SD = 0.25 11 n/a 21 4.72 (range 1–8) 0 0
Lai et al. 2012 Rani 15 5.1 (P < 0.001) 11 n/a 13 (at 3 months) 3.8 (range 3–6) 0 4
Bev 22 2.8 (P = 0.009) 13 2 20 (at 3 months) 3.8 (range 3–9) 0 5
Rani = ranibizumab; Bev = bevacizumab; BCVA = best corrected visual acuity; LMC = LogMar Chart; SD = standard deviation.
Figure 2. Best corrected visual acuity improvement at the end of the study periods (measured by LogMar Chart) (lines).
Figure 3. No. of patients with a best corrected visual acuity improvement of 3 lines or more.
152 M. Loutfi et al.The primary outcome measure was similar amongst all
studies, being the best corrected visual acuity measured
using the ETDRS chart, which was used in exactly the same
way.9,34,35 FFA and OCT were employed in each study to
assess for leakage sub/intraretinally.9,34,35 This could haveled to possible interpreter bias in our study due to having
technicians and doctors of varied experience in each study
examining the FFA and OCT scans.
There was no statistically significant heterogeneity in the
concentrations of drug used in injections and minimal heter-
Figure 4. No. of patients with an absence of leakage at follow up.
Figure 5. Overall number of injections required.
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each study, Gharbiya et al. and Iacono et al. provided one
injection and then continued on an as needed basis at
monthly follow ups whereas Lai et al. treated with three injec-
tions (one each month) before providing a course of three
injections (one each month) on an as needed basis.9,34,35
Of the three studies included in the meta-analysis, two
studies (Gharbiya et al. and Lai et al.) demonstrated similar
efficacies between ranibizumab and bevacizumab for the
treatment of myopic CNV, whereas Iacono et al. demon-
strated enhanced efficacy when using ranibizumab compared
to bevacizumab.9,34,35 This difference in results between
studies can lead to the effect size being unstable and there-
fore conclusions ought to be made with a degree of caution.Quality assessment
All studies used in the qualitative analysis scored highly in
the quality assessment (Tables 1 and 2). Iacono et al’s study
scored higher than Gharbiya et al’s study as it included allo-
cation concealment, was double blinded and analysis was
done on intention-to-treat basis.9,34Future studies
We did not analyse publication bias due to there being
less than 10 studies included in this review. There is likely
to be publication bias just by virtue of the low number of
studies and this is a limitation to our review. Further prospec-
tive, long-term, multi-centre randomised clinical trials are
required to determine the appropriate management of myo-
pic CNV. Due to the small research basis that currently exists
in the literature, it is inappropriate to reach a generalisableclinical judgement between ranibizumab and bevacizumab
for treating myopic CNV.Conclusion
Evidence suggests that intravitreal Anti-VEGF injections
should be first line therapy for myopic CNV. Comparative
studies examining intravitreal injections of ranibizumab and
intravitreal injections of bevacizumab indicate that they pro-
duce similar visual and anatomical outcomes. Both treat-
ments result in a statistically significant increase in visual
acuity with high numbers of patients maintaining stable
vision. Moreover, reduction of leakage in the retinal layers
following treatment is ubiquitous. Reported rates of ocular
and systemic complications suggest that both treatments
may be safe. However, more detailed documentation of both
systemic and ocular adverse events is required in future stud-
ies. Further prospective, long term, multi-centre randomised
clinical trials are still needed to elucidate the most appropri-
ate long term management of myopic CNV.Conflict of interest
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